<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37445986</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>13</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>28</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Unraveling Molecular and Genetic Insights into Neurodegenerative Diseases: Advances in Understanding Alzheimer's, Parkinson's, and Huntington's Diseases and Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10809</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241310809</ELocationID><Abstract><AbstractText>Neurodegenerative diseases are, according to recent studies, one of the main causes of disability and death worldwide. Interest in molecular genetics has started to experience exponential growth thanks to numerous advancements in technology, shifts in the understanding of the disease as a phenomenon, and the change in the perspective regarding gene editing and the advantages of this action. The aim of this paper is to analyze the newest approaches in genetics and molecular sciences regarding four of the most important neurodegenerative disorders: Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. We intend through this review to focus on the newest treatment, diagnosis, and predictions regarding this large group of diseases, in order to obtain a more accurate analysis and to identify the emerging signs that could lead to a better outcome in order to increase both the quality and the life span of the patient. Moreover, this review could provide evidence of future possible novel therapies that target the specific genes and that could be useful to be taken into consideration when the classical approaches fail to shed light.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ciurea</LastName><ForeName>Alexandru Vlad</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosurgery Department, Sanador Clinical Hospital, 010991 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Aurel George</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Bihor County Emergency Clinical Hospital, 410167 Oradea, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Faculty of Medicine, Oradea University, 410610 Oradea, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Covache-Busuioc</LastName><ForeName>Razvan-Adrian</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costin</LastName><ForeName>Horia-Petre</ForeName><Initials>HP</Initials><Identifier Source="ORCID">0000-0002-6347-9958</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glavan</LastName><ForeName>Luca-Andrei</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corlatescu</LastName><ForeName>Antonio-Daniel</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0009-0007-9232-1176</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saceleanu</LastName><ForeName>Vicentiu Mircea</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0002-4997-2690</Identifier><AffiliationInfo><Affiliation>Neurosurgery Department, Sibiu County Emergency Hospital, 550245 Sibiu, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosurgery Department, "Lucian Blaga" University of Medicine, 550024 Sibiu, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="Y">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">epigenetics</Keyword><Keyword MajorTopicYN="N">gene expression</Keyword><Keyword MajorTopicYN="N">molecular genetics</Keyword><Keyword MajorTopicYN="N">molecular pathology</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">therapeutic targets</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>13</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37445986</ArticleId><ArticleId IdType="pmc">PMC10341997</ArticleId><ArticleId IdType="doi">10.3390/ijms241310809</ArticleId><ArticleId IdType="pii">ijms241310809</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berry R.M. The genetic revolution and the physician&#x2019;s duty of confidentiality: The role of the old Hippocratic virtues in the regulation of the new genetic intimacy. BMJ. 1997;18:401&#x2013;441. doi: 10.1080/01947649709511044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01947649709511044</ArticleId><ArticleId IdType="pubmed">9433035</ArticleId></ArticleIdList></Reference><Reference><Citation>De Castro M. Johann Gregor Mendel: Paragon of experimental science. Mol. Genet. Genom. Med. 2016;4:3&#x2013;8. doi: 10.1002/mgg3.199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.199</ArticleId><ArticleId IdType="pmc">PMC4707027</ArticleId><ArticleId IdType="pubmed">26788542</ArticleId></ArticleIdList></Reference><Reference><Citation>Saceleanu V.M., Mohan A.G., Covache-Busuioc R.A., Costin H.P., Ciurea A.V. Wilhelm von Waldeyer: Important Steps in Neural Theory, Anatomy and Citology. Brain Sci. 2022;12:224. doi: 10.3390/brainsci12020224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci12020224</ArticleId><ArticleId IdType="pmc">PMC8869857</ArticleId><ArticleId IdType="pubmed">35203987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs G.G. Handbook of Clinical Neurology. Elsevier; Amsterdam, The Netherlands: 2018. Concepts and classification of neurodegenerative diseases; pp. 301&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-12-802395-2.00021-3</ArticleId><ArticleId IdType="pubmed">28987178</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Del Tredici K., Lee V.M.-Y., Trojanowski J.Q. Spreading of pathology in neurodegenerative diseases: A focus on human studies. Nat. Rev. Neurosci. 2015;16:109&#x2013;120. doi: 10.1038/nrn3887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3887</ArticleId><ArticleId IdType="pmc">PMC4312418</ArticleId><ArticleId IdType="pubmed">25588378</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.L., Lee V.M.Y. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 2014;20:130&#x2013;138. doi: 10.1038/nm.3457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3457</ArticleId><ArticleId IdType="pmc">PMC4011661</ArticleId><ArticleId IdType="pubmed">24504409</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani R.J., Rolston R.K., Smith M.A. Alzheimer Disease. Disease-a-Month. 2010;56:484&#x2013;546. doi: 10.1016/j.disamonth.2010.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.disamonth.2010.06.001</ArticleId><ArticleId IdType="pmc">PMC2941917</ArticleId><ArticleId IdType="pubmed">20831921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciurea V.A., Covache-Busuioc R.-A., Mohan A.G., Costin H.P., Voicu V., Academy B.R. Alzheimer&#x2019;s disease: 120 years of research and progress. J. Med. Life. 2023;16:173&#x2013;177. doi: 10.25122/jml-2022-0111.</Citation><ArticleIdList><ArticleId IdType="doi">10.25122/jml-2022-0111</ArticleId><ArticleId IdType="pmc">PMC10015576</ArticleId><ArticleId IdType="pubmed">36937482</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M., Reynolds C.A., Fratiglioni L., Johansson B., Mortimer J.A., Berg S., Fiske A., Pedersen N.L. Role of Genes and Environments for Explaining Alzheimer Disease. Arch. Gen. Psychiatry. 2006;63:168&#x2013;174. doi: 10.1001/archpsyc.63.2.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.2.168</ArticleId><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>An F., Zhao R., Xuan X., Xuan T., Zhang G., Wei C. Calycosin ameliorates advanced glycation end product-induced neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer&#x2019;s disease. Chem. Interact. 2022;368:110206. doi: 10.1016/j.cbi.2022.110206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2022.110206</ArticleId><ArticleId IdType="pubmed">36195188</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cauwenberghe C., Van Broeckhoven C., Sleegers K. The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Anesth. Analg. 2016;18:421&#x2013;430. doi: 10.1038/gim.2015.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.117</ArticleId><ArticleId IdType="pmc">PMC4857183</ArticleId><ArticleId IdType="pubmed">26312828</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts S., Ripellino J., Ingalls K., Robakis N., Felsenstein K. Non-amyloidogenic cleavage of the beta-amyloid precursor protein by an integral membrane metalloendopeptidase. J. Biol. Chem. 1994;269:3111&#x2013;3116. doi: 10.1016/S0021-9258(17)42055-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)42055-2</ArticleId><ArticleId IdType="pubmed">8300647</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C.-X., Wu Q., Sun J.-X., Song X.-H., Wang J., Xiong C.-Q., Teng F.-X. Blocking beta 2-adrenergic receptor inhibits dendrite ramification in a mouse model of Alzheimer&#x2019;s disease. Neural Regen. Res. 2017;12:1499&#x2013;1506. doi: 10.4103/1673-5374.215261.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.215261</ArticleId><ArticleId IdType="pmc">PMC5649472</ArticleId><ArticleId IdType="pubmed">29089997</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M., Tagami S., Yanagida K., Takami M., Kodama T.S., Mori K., Nakayama T., Ihara Y., Takeda M. &#x3b3;-Secretase Modulators and Presenilin 1 Mutants Act Differently on Presenilin/&#x3b3;-Secretase Function to Cleave A&#x3b2;42 and A&#x3b2;43. Cell Rep. 2013;3:42&#x2013;51. doi: 10.1016/j.celrep.2012.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.11.028</ArticleId><ArticleId IdType="pubmed">23291095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H., Hu Y., Hardy J., Blennow K., Chen C., Perry G., Kim S.H., Villemagne V.L., Aisen P., Vendruscolo M., et al. The amyloid-&#x3b2; pathway in Alzheimer&#x2019;s disease: A plain language summary. Neurodegener. Dis. Manag. 2023;13:141&#x2013;201. doi: 10.2217/nmt-2022-0037.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt-2022-0037</ArticleId><ArticleId IdType="pmc">PMC10334247</ArticleId><ArticleId IdType="pubmed">36994753</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosh J.L., Rhymes E.R., Mumford P., Whittaker H.T., Pulford L.J., Noy S.J., Cleverley K., Strydom A., Fisher E.M.C., Wiseman F.K., et al. Genetic dissection of down syndrome-associated alterations in APP/amyloid-&#x3b2; biology using mouse models. Sci. Rep. 2021;11:5736. doi: 10.1038/s41598-021-85062-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85062-3</ArticleId><ArticleId IdType="pmc">PMC7952899</ArticleId><ArticleId IdType="pubmed">33707583</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., Atwal J.K., Steinberg S., Snaedal J., Jonsson P.V., Bjornsson S., Stefansson H., Sulem P., Gudbjartsson D.F., Maloney J., et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99. doi: 10.1038/nature11283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11283</ArticleId><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I., Gallardo R., Ungureanu A.-A., Cano V.C., Snellinx A., Ramakers M., Bartic C., Rousseau F., Schymkowitz J., De Strooper B. The Alzheimer Disease Protective Mutation A2T Modulates Kinetic and Thermodynamic Properties of Amyloid-&#x3b2; (A&#x3b2;) Aggregation. J. Biol. Chem. 2014;289:30977&#x2013;30989. doi: 10.1074/jbc.M114.599027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.599027</ArticleId><ArticleId IdType="pmc">PMC4223304</ArticleId><ArticleId IdType="pubmed">25253695</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.-W., He Y.-H., Zhang Y.-X., Cai W.-W., Yang L.-Q., Xu L.-Y., Kong Q.-P. Absence of A673T variant in APP gene indicates an alternative protective mechanism contributing to longevity in Chinese individuals. Neurobiol. Aging. 2014;35:935.e11&#x2013;935.e12. doi: 10.1016/j.neurobiolaging.2013.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.09.023</ArticleId><ArticleId IdType="pubmed">24126161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengel-From J., Jeune B., Pentti T., McGue M., Christensen K., Christiansen L. The APP A673T frequency differs between Nordic countries. Neurobiol. Aging. 2015;36:2909.e1&#x2013;2909.e4. doi: 10.1016/j.neurobiolaging.2015.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.07.011</ArticleId><ArticleId IdType="pmc">PMC4562869</ArticleId><ArticleId IdType="pubmed">26239177</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaccone G., Morbin M., Moda F., Botta M., Mazzoleni G., Uggetti A., Catania M., Moro M.L., Redaelli V., Spagnoli A., et al. Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathol. 2010;120:803&#x2013;812. doi: 10.1007/s00401-010-0747-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0747-1</ArticleId><ArticleId IdType="pubmed">20842367</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne V.L., Ataka S., Mizuno T., Brooks W.S., Wada Y., Kondo M., Jones G., Watanabe Y., Mulligan R.S., Nakagawa M., et al. High Striatal Amyloid &#x3b2;-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types. Arch. Neurol. 2009;66:1537&#x2013;1544. doi: 10.1001/archneurol.2009.285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.285</ArticleId><ArticleId IdType="pubmed">20008660</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B., Haure-Mirande J.-V., Zhang B., Haroutunian V., Gandy S., Schadt E.E., Dudley J.T., Ehrlich M.E. Molecular systems evaluation of oligomerogenic APPE693Q and fibrillogenic APPKM670/671NL/PSEN1&#x394;exon9 mouse models identifies shared features with human Alzheimer&#x2019;s brain molecular pathology. Mol. Psychiatry. 2016;21:1099&#x2013;1111. doi: 10.1038/mp.2015.167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.167</ArticleId><ArticleId IdType="pmc">PMC4862938</ArticleId><ArticleId IdType="pubmed">26552589</ArticleId></ArticleIdList></Reference><Reference><Citation>Natt&#xe9; R., Maat-Schieman M.L.C., Haan J., Bornebroek M., Roos R.A., Van Duinen S.G. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann. Neurol. 2001;50:765&#x2013;772. doi: 10.1002/ana.10040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10040</ArticleId><ArticleId IdType="pubmed">11761474</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishitsuji K., Tomiyama T., Ishibashi K., Kametani F., Ozawa K., Okada R., Maat-Schieman M.L., Roos R.A., Iwai K., Mori H. Cerebral vascular accumulation of Dutch-type A&#x3b2;42, but not wild-type A&#x3b2;42, in hereditary cerebral hemorrhage with amyloidosis, Dutch type. J. Neurosci. Res. 2007;85:2917&#x2013;2923. doi: 10.1002/jnr.21413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21413</ArticleId><ArticleId IdType="pubmed">17628026</ArticleId></ArticleIdList></Reference><Reference><Citation>Uddin M.S., Tewari D., Sharma G., Kabir M.T., Barreto G.E., Bin-Jumah M.N., Perveen A., Abdel-Daim M.M., Ashraf G.M. Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer&#x2019;s Disease. Mol. Neurobiol. 2020;57:2902&#x2013;2919. doi: 10.1007/s12035-020-01929-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-01929-y</ArticleId><ArticleId IdType="pubmed">32430843</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberdi E., Wyssenbach A., Alberdi M., S&#xe1;nchez-G&#xf3;mez M.V., Cavaliere F., Rodr&#xed;guez J.J., Verkhratsky A., Matute C. Ca2+-dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid &#x3b2;-treated astrocytes and in a model of Alzheimer&#x2019;s disease. Aging Cell. 2013;12:292&#x2013;302. doi: 10.1111/acel.12054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12054</ArticleId><ArticleId IdType="pubmed">23409977</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T., Nagata T., Shimada H., Teraoka R., Fukushima A., Kanemitsu H., Takuma H., Kuwano R., Imagawa M., Ataka S., et al. A new amyloid &#x3b2; variant favoring oligomerization in Alzheimer&#x2019;s-type dementia. Ann. Neurol. 2008;63:377&#x2013;387. doi: 10.1002/ana.21321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21321</ArticleId><ArticleId IdType="pubmed">18300294</ArticleId></ArticleIdList></Reference><Reference><Citation>McKnelly K.J., Kreutzer A.G., Howitz W.J., Haduong K., Yoo S., Hart C., Nowick J.S. Effects of Familial Alzheimer&#x2019;s Disease Mutations on the Assembly of a &#x3b2;-Hairpin Peptide Derived from A&#x3b2;16&#x2013;36. Biochemistry. 2022;61:446&#x2013;454. doi: 10.1021/acs.biochem.1c00664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.1c00664</ArticleId><ArticleId IdType="pmc">PMC9042424</ArticleId><ArticleId IdType="pubmed">35213141</ArticleId></ArticleIdList></Reference><Reference><Citation>Paik Y.K., Chang D.J., Reardon C.A., Walker M.D., Taxman E., Taylor J.M. Identification and characterization of transcriptional regulatory regions associated with expression of the human apolipoprotein E gene. J. Biol. Chem. 1988;263:13340&#x2013;13349. doi: 10.1016/S0021-9258(18)37710-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)37710-X</ArticleId><ArticleId IdType="pubmed">3166458</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney B., Ge Y.-W., Alley G.M., Lahiri D.K. Important differences between human and mouse APOE gene promoters: Limitation of mouse APOE model in studying Alzheimer&#x2019;s disease. J. Neurochem. 2007;103:1237&#x2013;1257. doi: 10.1111/j.1471-4159.2007.04831.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04831.x</ArticleId><ArticleId IdType="pubmed">17854398</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee A., Tsui N.B., Kwan R.Y., Leung A.Y., Lai C.K., Chung T., Lau J.Y., Fok M., Dai D.L., Lau L.-T. Apolipoprotein E Gene Revisited: Contribution of Rare Variants to Alzheimer&#x2019;s Disease Susceptibility in Southern Chinese. Curr. Alzheimer Res. 2021;18:67&#x2013;79. doi: 10.2174/1567205018666210324111401.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205018666210324111401</ArticleId><ArticleId IdType="pubmed">33761857</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., M&#xe4;gi R., Milani L., Lauschke V.M. Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk. J. Lipid Res. 2018;59:1987&#x2013;2000. doi: 10.1194/jlr.P086710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.P086710</ArticleId><ArticleId IdType="pmc">PMC6168301</ArticleId><ArticleId IdType="pubmed">30076208</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A.M. Gene identification in Alzheimer&#x2019;s disease. Pharmacogenomics. 2001;2:239&#x2013;249. doi: 10.1517/14622416.2.3.239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14622416.2.3.239</ArticleId><ArticleId IdType="pubmed">11535112</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J., Del-Favero J., Dermaut B., van Duijn C.M., Backhovens H., Broeck M.V.D., Serneels S., Corsmit E., Van Broeckhoven C., Cruts M. Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer&#x2019;s disease and variable expression. Hum. Mol. Genet. 2000;9:325&#x2013;331. doi: 10.1093/hmg/9.3.325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/9.3.325</ArticleId><ArticleId IdType="pubmed">10655540</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M., Theuns J., Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 2012;33:1340&#x2013;1344. doi: 10.1002/humu.22117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22117</ArticleId><ArticleId IdType="pmc">PMC3465795</ArticleId><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Zhou R., Yang G., Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A&#x3b2;42 and A&#x3b2;40 peptides by &#x3b3;-secretase. Proc. Natl. Acad. Sci. USA. 2016;114:E476&#x2013;E485. doi: 10.1073/pnas.1618657114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1618657114</ArticleId><ArticleId IdType="pmc">PMC5278480</ArticleId><ArticleId IdType="pubmed">27930341</ArticleId></ArticleIdList></Reference><Reference><Citation>Wines-Samuelson M., Schulte E.C., Smith M.J., Aoki C., Liu X., Kelleher R.J., Shen J. Characterization of Age-Dependent and Progressive Cortical Neuronal Degeneration in Presenilin Conditional Mutant Mice. PLoS ONE. 2010;5:e10195. doi: 10.1371/journal.pone.0010195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010195</ArticleId><ArticleId IdType="pmc">PMC2855368</ArticleId><ArticleId IdType="pubmed">20419112</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe J.S.K., Jacquart S., Chakraverty S., Wang J., Mayo K., Fagan A.M., Holtzman D.M., Morris J.C., Goate A.M. Extreme cerebrospinal fluid amyloid &#x3b2; levels identify family with late-onset Alzheimer&#x2019;s disease presenilin 1 mutation. Ann. Neurol. 2007;61:446&#x2013;453. doi: 10.1002/ana.21099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21099</ArticleId><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S., Theuns J., Van Broeck B., Pirici D., Vennekens K., Corsmit E., Cruts M., Dermaut B., Wang R., Van Broeckhoven C. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased A&#x3b2;42 and decreased A&#x3b2;40. Hum. Mutat. 2006;27:686&#x2013;695. doi: 10.1002/humu.20336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20336</ArticleId><ArticleId IdType="pubmed">16752394</ArticleId></ArticleIdList></Reference><Reference><Citation>Koriath C., Kenny J., Adamson G., Druyeh R., Taylor W., Beck J., Quinn L., Mok T.H., Dimitriadis A., Norsworthy P., et al. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Mol. Psychiatry. 2020;25:3399&#x2013;3412. doi: 10.1038/s41380-018-0224-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0224-0</ArticleId><ArticleId IdType="pmc">PMC6330090</ArticleId><ArticleId IdType="pubmed">30279455</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo M., Frangipane F., Cupidi C., De Bartolo M., Turone S., Ferrari C., Nacmias B., Grimaldi G., Lagan&#xe0; V., Colao R., et al. The novel PSEN1 M84V mutation associated to frontal dysexecutive syndrome, spastic paraparesis, and cerebellar atrophy in a dominant Alzheimer&#x2019;s disease family. Neurobiol. Aging. 2017;56:213.e7&#x2013;213.e12. doi: 10.1016/j.neurobiolaging.2017.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.04.017</ArticleId><ArticleId IdType="pubmed">28532646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu S., Gordon B.A., Hornbeck R., Norton J.B., Levitch D., Louden A., Ziegemeier E., Laforce R., Jr., Chhatwal J., Day G.S., et al. Discovery and validation of autosomal dominant Alzheimer&#x2019;s disease mutations. Alzheimers Res. Ther. 2018;10:67. doi: 10.1186/s13195-018-0392-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0392-9</ArticleId><ArticleId IdType="pmc">PMC6052673</ArticleId><ArticleId IdType="pubmed">30021643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N., Takami M., Okochi M., Kasuga K., Ihara Y., Ikeuchi T. Switched A&#x3b2;43 generation in familial Alzheimer&#x2019;s disease with presenilin 1 mutation. Transl. Psychiatry. 2021;11:558. doi: 10.1038/s41398-021-01684-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-021-01684-1</ArticleId><ArticleId IdType="pmc">PMC8564532</ArticleId><ArticleId IdType="pubmed">34728605</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Garc&#xed;a S., Jim&#xe9;nez-Bonilla J., Delgado A.L., Balaguer P.O., Ceberio J.I., Marraco I.B., Rodr&#xed;guez E.R., S&#xe1;nchez-Juan P. A Rare PSEN1 (Leu85Pro) Mutation Causing Alzheimer&#x2019;s Disease in a 29-Year-Old Woman Presenting as Corticobasal Syndrome. J. Alzheimers Dis. 2019;70:655&#x2013;658. doi: 10.3233/JAD-190107.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-190107</ArticleId><ArticleId IdType="pubmed">31282415</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber C., Llerena C.V., Toombs J., Pocock J.M., Ryan N.S., Fox N.C., Zetterberg H., Hardy J., Wray S. Amyloid precursor protein processing in human neurons with an allelic series of the PSEN1 intron 4 deletion mutation and total presenilin-1 knockout. Brain Commun. 2019;1:fcz024. doi: 10.1093/braincomms/fcz024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcz024</ArticleId><ArticleId IdType="pmc">PMC7212081</ArticleId><ArticleId IdType="pubmed">32395715</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jonghe C., Cruts M., Rogaeva E.A., Tysoe C., Singleton A., Vanderstichele H., Meschino W., Dermaut B., Vanderhoeven I., Backhovens H., et al. Aberrant Splicing in the Presenilin-1 Intron 4 Mutation Causes Presenile Alzheimer&#x2019;s Disease by Increased A 42 Secretion. Hum. Mol. Genet. 1999;8:1529&#x2013;1540. doi: 10.1093/hmg/8.8.1529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.8.1529</ArticleId><ArticleId IdType="pubmed">10401002</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaruga-Bracke M., Veugelen S., Benurwar M., Lismont S., Sepulveda-Falla D., Lleo A., Ryan N.S., Lashley T., Fox N., Murayama S., et al. Qualitative changes in human &#x3b3;-secretase underlie familial Alzheimer&#x2019;s disease. J. Exp. Med. 2015;212:2003&#x2013;2013. doi: 10.1084/jem.20150892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20150892</ArticleId><ArticleId IdType="pmc">PMC4647268</ArticleId><ArticleId IdType="pubmed">26481686</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox N.C., Kennedy A.M., Harvey R.J., Lantos P.L., Roques P.K., Collinge J., Hardy J., Hutton M., Stevens J.M., Warrington E.K., et al. Clinicopathological features of familial Alzheimer&#x2019;s disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain. 1997;120:491&#x2013;501. doi: 10.1093/brain/120.3.491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/120.3.491</ArticleId><ArticleId IdType="pubmed">9126060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L., Bammens L., Benilova I., Vandersteen A., Benurwar M., Borgers M., Lismont S., Zhou L., Van Cleynenbreugel S., Esselmann H., et al. The mechanism of &#x3b3;-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261&#x2013;2274. doi: 10.1038/emboj.2012.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.79</ArticleId><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman J.M., Gylys K.H., Medina L.D., Fox M., Kepe V., Flores D.L., Apostolova L.G., Barrio J.R., Small G., Silverman D.H., et al. Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer&#x2019;s disease due to a novel PSEN1 mutation. Neurosci. Lett. 2011;487:287&#x2013;292. doi: 10.1016/j.neulet.2010.10.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.10.039</ArticleId><ArticleId IdType="pmc">PMC3034479</ArticleId><ArticleId IdType="pubmed">21094210</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi G., Fotiou A., Jyrinji D., Tycko B., DeArmand S., Rogaeva E., Song Y.-Q., Medieros H., Liang Y., Orlacchio A., et al. Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. Arch. Neurol. 2000;57:1454&#x2013;1457. doi: 10.1001/archneur.57.10.1454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.10.1454</ArticleId><ArticleId IdType="pubmed">11030797</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., et al. Candidate gene for the chromosome 1 familial Alzheimer&#x2019;s disease locus. Science. 1995;269:973&#x2013;977. doi: 10.1126/science.7638622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7638622</ArticleId><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone F., Cacace R., Van Mossevelde S., Bossche T.V.D., De Deyn P.P., Cras P., Engelborghs S., van der Zee J., Van Broeckhoven C. Genetic screening in early-onset dementia patients with unclear phenotype: Relevance for clinical diagnosis. Neurobiol. Aging. 2018;69:292.e7&#x2013;292.e14. doi: 10.1016/j.neurobiolaging.2018.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.04.015</ArticleId><ArticleId IdType="pubmed">29859640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia L., Fu Y., Shen L., Zhang H., Zhu M., Qiu Q., Wang Q., Yan X., Kong C., Hao J., et al. PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer&#x2019;s disease. Alzheimers Dement. 2020;16:178&#x2013;191. doi: 10.1002/alz.12005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12005</ArticleId><ArticleId IdType="pubmed">31914229</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang Y., Li T., Wang Q., Qin W., Li Y., Wei Y., Jia L. A Rare Variation in the 3&#x2032; Untranslated Region of the Presenilin 2 Gene Is Linked to Alzheimer&#x2019;s Disease. Mol. Neurobiol. 2021;58:4337&#x2013;4347. doi: 10.1007/s12035-021-02429-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02429-3</ArticleId><ArticleId IdType="pubmed">34009547</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallon D., Rousseau S., Rovelet-Lecrux A., Quillard-Muraine M., Guyant-Mar&#xe9;chal L., Martinaud O., Pariente J., Puel M., Rollin-Sillaire A., Pasquier F., et al. The French Series of Autosomal Dominant Early Onset Alzheimer&#x2019;s Disease Cases: Mutation Spectrum and Cerebrospinal Fluid Biomarkers. J. Alzheimers Dis. 2012;30:847&#x2013;856. doi: 10.3233/JAD-2012-120172.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120172</ArticleId><ArticleId IdType="pubmed">22475797</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcon G., Giaccone G., Cupidi C., Balestrieri M., Beltrami C.A., Finato N., Bergonzi P., Sorbi S., Bugiani O., Tagliavini F. Neuropathological and Clinical Phenotype of an Italian Alzheimer Family with M239V Mutation of Presenilin 2 Gene. J. Neuropathol. Exp. Neurol. 2004;63:199&#x2013;209. doi: 10.1093/jnen/63.3.199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/63.3.199</ArticleId><ArticleId IdType="pubmed">15055444</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Weisgraber K.H., Mucke L., Mahley R.W. Apolipoprotein E: Diversity of Cellular Origins, Structural and Biophysical Properties, and Effects in Alzheimer&#x2019;s Disease. J. Mol. Neurosci. 2004;23:189&#x2013;204. doi: 10.1385/JMN:23:3:189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:23:3:189</ArticleId><ArticleId IdType="pubmed">15181247</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat. Rev. Neurol. 2013;9:106&#x2013;118. doi: 10.1038/nrneurol.2012.263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.263</ArticleId><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara E., Marks J.D., Fan Z., Klickstein J.A., Roe A.D., Krogh K.A., Wegmann S., Maesako M., Luo C.C., Mylvaganam R., et al. Isoform- and cell type-specific structure of apolipoprotein E lipoparticles as revealed by a novel Forster resonance energy transfer assay. J. Biol. Chem. 2017;292:14720&#x2013;14729. doi: 10.1074/jbc.M117.784264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.784264</ArticleId><ArticleId IdType="pmc">PMC5592654</ArticleId><ArticleId IdType="pubmed">28684412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.-T., Seo J., Gao F., Feldman H.M., Wen H.-L., Penney J., Cam H.P., Gjoneska E., Raja W.K., Cheng J., et al. APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer&#x2019;s Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron. 2018;98:1141&#x2013;1154.e7. doi: 10.1016/j.neuron.2018.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.008</ArticleId><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S.S., Ebbert M.T.W., Baker K.E., Cook C., Wang X., Sens J.P., Kocher J.-P., Petrucelli L., Fryer J.D. Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J. Exp. Med. 2018;215:2235&#x2013;2245. doi: 10.1084/jem.20180653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180653</ArticleId><ArticleId IdType="pmc">PMC6122978</ArticleId><ArticleId IdType="pubmed">30082275</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Davila-Velderrain J., Peng Z., Gao F., Mohammadi S., Young J.Z., Menon M., He L., Abdurrob F., Jiang X., et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337. doi: 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J., Benedet A.L., Pascoal T.A., Mathotaarachchi S., Chamoun M., Savard M., Thomas E., Kang M.S., Lussier F., Tissot C., et al. Association of Apolipoprotein E &#x3b5;4 With Medial Temporal Tau Independent of Amyloid-&#x3b2;. JAMA Neurol. 2020;77:470&#x2013;479. doi: 10.1001/jamaneurol.2019.4421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4421</ArticleId><ArticleId IdType="pmc">PMC6990684</ArticleId><ArticleId IdType="pubmed">31860000</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Alzheimer&#x2019;s Disease Neuroimaging Initiative. Yamada K., Liddelow S.A., Smith S.T., Zhao L., Luo W., Tsai R.M., Spina S., Grinberg L.T., et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527. doi: 10.1038/nature24016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris F.M., Brecht W.J., Xu Q., Mahley R.W., Huang Y. Increased tau Phosphorylation in Apolipoprotein E4 Transgenic Mice Is Associated with Activation of Extracellular Signal-regulated Kinase. J. Biol. Chem. 2004;279:44795&#x2013;44801. doi: 10.1074/jbc.M408127200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M408127200</ArticleId><ArticleId IdType="pubmed">15322121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadhwani A.R., Affaneh A., Van Gulden S., Kessler J.A. Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease. Ann. Neurol. 2019;85:726&#x2013;739. doi: 10.1002/ana.25455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25455</ArticleId><ArticleId IdType="pmc">PMC8123085</ArticleId><ArticleId IdType="pubmed">30840313</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibb G.M., Pearce J., Betts J.C., Lovestone S., Hoffmann M.M., Maerz W., Blackstock W.P., Anderton B.H. Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3&#x3b2; identified by nano-electrospray mass spectrometry. FEBS Lett. 2000;485:99&#x2013;103. doi: 10.1016/S0014-5793(00)02196-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(00)02196-7</ArticleId><ArticleId IdType="pubmed">11094148</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.-S., Ji-Seon P., Sang-Wook K., Kang M.-J., Kang S.-W., Kim D.-H., Yoon S.-Y. Disease-Associated Mutations of TREM2 Alter the Processing of N-Linked Oligosaccharides in the Golgi Apparatus. Traffic. 2015;16:510&#x2013;518. doi: 10.1111/tra.12264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tra.12264</ArticleId><ArticleId IdType="pubmed">25615530</ArticleId></ArticleIdList></Reference><Reference><Citation>Saceleanu V.M., Covache-Busuioc R.-A., Costin H.-P., Glavan L.-A., Ciurea A.V. An Important Step in Neuroscience: Camillo Golgi and His Discoveries. Cells. 2022;11:4112. doi: 10.3390/cells11244112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11244112</ArticleId><ArticleId IdType="pmc">PMC9776620</ArticleId><ArticleId IdType="pubmed">36552876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J.D., Ulland T.K., Mahan T.E., Nystr&#xf6;m S., Nilsson K.P., Song W.M., Zhou Y., Reinartz M., Choi S., Jiang H., et al. ApoE facilitates the microglial response to amyloid plaque pathology. J. Exp. Med. 2018;215:1047&#x2013;1058. doi: 10.1084/jem.20171265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171265</ArticleId><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B., et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 2017;169:1276&#x2013;1290.e17. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705. doi: 10.1038/31508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Bird T.D., Ghetti B. Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A New Group of Tauopathies. Brain Pathol. 2006;8:387&#x2013;402. doi: 10.1111/j.1750-3639.1998.tb00162.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.1998.tb00162.x</ArticleId><ArticleId IdType="pmc">PMC8098460</ArticleId><ArticleId IdType="pubmed">9546295</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998;43:815&#x2013;825. doi: 10.1002/ana.410430617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430617</ArticleId><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron. 1989;3:519&#x2013;526. doi: 10.1016/0896-6273(89)90210-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(89)90210-9</ArticleId><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudier J., Cole R. D Interactions between the microtubule-associated tau proteins and S100b regulate tau phosphorylation by the Ca2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 1988;263:5876&#x2013;5883. doi: 10.1016/S0021-9258(18)60647-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)60647-7</ArticleId><ArticleId IdType="pubmed">2833519</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewes G., Ebneth A., Preuss U., Mandelkow E.-M., Mandelkow E. MARK, a Novel Family of Protein Kinases That Phosphorylate Microtubule-Associated Proteins and Trigger Microtubule Disruption. Cell. 1997;89:297&#x2013;308. doi: 10.1016/S0092-8674(00)80208-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80208-1</ArticleId><ArticleId IdType="pubmed">9108484</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewes G., Lichtenberg-Kraag B., D&#xf6;ring F., Mandelkow E., Biernat J., Goris J., Dor&#xe9;e M., Mandelkow E. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J. 1992;11:2131&#x2013;2138. doi: 10.1002/j.1460-2075.1992.tb05272.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1992.tb05272.x</ArticleId><ArticleId IdType="pmc">PMC556680</ArticleId><ArticleId IdType="pubmed">1376245</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C., Brunner C., Lassmann H., Budka H., Jellinger K., Wiche G., Seitelberger F., Grundke-Iqbal I., Iqbal K., Wisniewski H. Accumulation of abnormally phosphorylated &#x3c4; precedes the formation of neurofibrillary tangles in Alzheimer&#x2019;s disease. Brain Res. 1989;477:90&#x2013;99. doi: 10.1016/0006-8993(89)91396-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(89)91396-6</ArticleId><ArticleId IdType="pubmed">2495152</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P., Vincent I.J. On the role of tau phosphorylation in the formation of PHF. Neurobiol. Aging. 1995;16:420&#x2013;422. doi: 10.1016/0197-4580(95)00039-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00039-H</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.-Z., Wu Q., Smith A., Grundke-Iqbal I., Iqbal K. &#x3c4; is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett. 1998;436:28&#x2013;34. doi: 10.1016/S0014-5793(98)01090-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(98)01090-4</ArticleId><ArticleId IdType="pubmed">9771888</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda M., Takamatsu J., D&#x2019;Souza I., Crowther R.A., Kawamata T., Hasegawa M., Hasegawa H., Spillantini M.G., Tanimukai S., Poorkaj P., et al. A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto) Ann. Neurol. 2000;47:422&#x2013;429. doi: 10.1002/1531-8249(200004)47:4&lt;422::AID-ANA4&gt;3.0.CO;2-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(200004)47:4&lt;422::AID-ANA4&gt;3.0.CO;2-G</ArticleId><ArticleId IdType="pubmed">10762152</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamatsu J., Kondo A., Ikegami K., Kimura T., Fujii H., Mitsuyama Y., Hashizume Y. Selective Expression of Ser 199/202 Phosphorylated Tau in a Case of Frontotemporal Dementia. Dement. Geriatr. Cogn. Disord. 1998;9:82&#x2013;89. doi: 10.1159/000017028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000017028</ArticleId><ArticleId IdType="pubmed">9524799</ArticleId></ArticleIdList></Reference><Reference><Citation>Labb&#xe9; C., Ogaki K., Lorenzo-Betancor O., Soto-Ortolaza A.I., Walton R.L., Rayaprolu S., Fujioka S., Murray M.E., Heckman M.G., Puschmann A., et al. Role for the microtubule-associated protein tau variant p.A152T in risk of &#x3b1;-synucleinopathies. Neurology. 2015;85:1680&#x2013;1686. doi: 10.1212/WNL.0000000000001946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001946</ArticleId><ArticleId IdType="pmc">PMC4653108</ArticleId><ArticleId IdType="pubmed">26333800</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S.C., Pastor P., Cooper B., Cervantes S., Benitez B.A., Razquin C., Goate A., Cruchaga C., Ibero-American Alzheimer Disease Genetics Group Researchers Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer&#x2019;s disease Ibero-American cohort. Alzheimers Res. Ther. 2012;4:34. doi: 10.1186/alzrt137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt137</ArticleId><ArticleId IdType="pmc">PMC3506948</ArticleId><ArticleId IdType="pubmed">22906081</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G., Chinnathambi S., Lee J.J., Dombroski B.A., Baker M.C., Soto-Ortolaza A.I., Lee S.E., Klein E., Huang A.Y., Sears R., et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer&#x2019;s diseases. Hum. Mol. Genet. 2012;21:3500&#x2013;3512. doi: 10.1093/hmg/dds161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds161</ArticleId><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzini C., Goedert M., Hodges J.R., Smith M.J., Jakes R., Hills R., Xuereb J.H., Crowther R.A., Spillantini M.G. Tau Gene Mutation K257T Causes a Tauopathy Similar to Pick&#x2019;s Disease. J. Neuropathol. Exp. Neurol. 2000;59:990&#x2013;1001. doi: 10.1093/jnen/59.11.990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/59.11.990</ArticleId><ArticleId IdType="pubmed">11089577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T., Ota S., Tanaka K., Ito Y., Hasegawa M., Umeda Y., Motoi Y., Takanashi M., Yasuhara M., Anno M., et al. A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. Ann. Neurol. 2003;53:133&#x2013;137. doi: 10.1002/ana.10447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10447</ArticleId><ArticleId IdType="pubmed">12509859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg M., Grujic Z.M., Baker M., Demirci S., Guillozet A.L., Sweet A.P., Herzog L.L., Weintraub S., Mesulam M.-M., LaPointe N.E., et al. The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. Acta Neuropathol. 2003;106:323&#x2013;336. doi: 10.1007/s00401-003-0734-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-003-0734-x</ArticleId><ArticleId IdType="pubmed">12883828</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., et al. Glutaminyl cyclase inhibition attenuates pyroglutamate A&#x3b2; and Alzheimer&#x2019;s disease&#x2013;like pathology. Nat. Med. 2008;14:1106&#x2013;1111. doi: 10.1038/nm.1872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1872</ArticleId><ArticleId IdType="pubmed">18836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost J.L., Liu B., Kleinschmidt M., Schilling S., Demuth H.-U., Lemere C.A. Passive Immunization against Pyroglutamate-3 Amyloid-&#x3b2; Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study. Neurodegener. Dis. 2012;10:265&#x2013;270. doi: 10.1159/000335913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000335913</ArticleId><ArticleId IdType="pmc">PMC3702016</ArticleId><ArticleId IdType="pubmed">22343072</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost J.L., Liu B., Rahfeld J.-U., Kleinschmidt M., O&#x2019;Nuallain B., Le K.X., Lues I., Caldarone B.J., Schilling S., Demuth H.-U., et al. An anti-pyroglutamate-3 A&#x3b2; vaccine reduces plaques and improves cognition in APPswe/PS1&#x394;E9 mice. Neurobiol. Aging. 2015;36:3187&#x2013;3199. doi: 10.1016/j.neurobiolaging.2015.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.08.021</ArticleId><ArticleId IdType="pmc">PMC4641825</ArticleId><ArticleId IdType="pubmed">26453001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann T., Meyer A., Heiser U., Kurat S., B&#xf6;hme L., Kleinschmidt M., B&#xfc;hring K.-U., Hutter-Paier B., Farcher M., DeMuth H.-U., et al. Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer&#x2019;s Disease&#x2014;Studies on Relation to Effective Target Occupancy. Experiment. 2017;362:119&#x2013;130. doi: 10.1124/jpet.117.240614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.117.240614</ArticleId><ArticleId IdType="pubmed">28446518</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R.B., Lu J., Tang Y., Racke M.M., DeLong C.A., Tzaferis J.A., Hole J.T., Forster B.M., McDonnell P.C., Liu F., et al. A Plaque-Specific Antibody Clears Existing &#x3b2;-amyloid Plaques in Alzheimer&#x2019;s Disease Mice. Neuron. 2012;76:908&#x2013;920. doi: 10.1016/j.neuron.2012.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.10.029</ArticleId><ArticleId IdType="pubmed">23217740</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe S.L., Willis B.A., Hawdon A., Natanegara F., Chua L., Foster J., Shcherbinin S., Ardayfio P., Sims J.R. Donanemab (LY3002813) dose-escalation study in Alzheimer&#x2019;s disease. Alzheimers Dement. Transl. Res. Clin. Interv. 2021;7:e12112. doi: 10.1002/trc2.12112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12112</ArticleId><ArticleId IdType="pmc">PMC7882532</ArticleId><ArticleId IdType="pubmed">33614890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe S.L., Evans C.D., Shcherbinin S., Cheng Y.-J., Willis B.A., Gueorguieva I., Lo A.C., Fleisher A.S., Dage J.L., Ardayfio P., et al. Donanemab (LY3002813) Phase 1b Study in Alzheimer&#x2019;s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. J. Prev. Alzheimers Dis. 2021;8:414&#x2013;424. doi: 10.14283/jpad.2021.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2021.56</ArticleId><ArticleId IdType="pubmed">34585215</ArticleId></ArticleIdList></Reference><Reference><Citation>Shcherbinin S., Evans C.D., Lu M., Andersen S.W., Pontecorvo M.J., Willis B.A., Gueorguieva I., Hauck P.M., Brooks D.A., Mintun M.A., et al. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: The TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79:1015. doi: 10.1001/jamaneurol.2022.2793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.2793</ArticleId><ArticleId IdType="pmc">PMC9468959</ArticleId><ArticleId IdType="pubmed">36094645</ArticleId></ArticleIdList></Reference><Reference><Citation>Raza C., Anjum R., Shakeel N.U.A. Parkinson&#x2019;s disease: Mechanisms, translational models and management strategies. Life Sci. 2019;226:77&#x2013;90. doi: 10.1016/j.lfs.2019.03.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.03.057</ArticleId><ArticleId IdType="pubmed">30980848</ArticleId></ArticleIdList></Reference><Reference><Citation>Beitz J.M. Parkinson s disease: A review. Front. Biosci. 2014;S6:65&#x2013;74. doi: 10.2741/S415.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/S415</ArticleId><ArticleId IdType="pubmed">24389262</ArticleId></ArticleIdList></Reference><Reference><Citation>Day J.O., Mullin S. The Genetics of Parkinson&#x2019;s Disease and Implications for Clinical Practice. Genes. 2021;12:1006. doi: 10.3390/genes12071006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12071006</ArticleId><ArticleId IdType="pmc">PMC8304082</ArticleId><ArticleId IdType="pubmed">34208795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye H., Robak L.A., Yu M., Cykowski M., Shulman J.M. Genetics and Pathogenesis of Parkinson&#x2019;s Syndrome. Annu. Rev. Pathol. Mech. Dis. 2023;18:95&#x2013;121. doi: 10.1146/annurev-pathmechdis-031521-034145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathmechdis-031521-034145</ArticleId><ArticleId IdType="pmc">PMC10290758</ArticleId><ArticleId IdType="pubmed">36100231</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui I.J., Pervaiz N., Abbasi A.A. The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication. Sci. Rep. 2016;6:24475. doi: 10.1038/srep24475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24475</ArticleId><ArticleId IdType="pmc">PMC4832246</ArticleId><ArticleId IdType="pubmed">27080380</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui Q., Ni H., Li D., Gao R., Chen G. The Role of LRRK2 in Neurodegeneration of Parkinson Disease. Curr. Neuropharmacol. 2018;16:1348&#x2013;1357. doi: 10.2174/1570159X16666180222165418.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X16666180222165418</ArticleId><ArticleId IdType="pmc">PMC6251048</ArticleId><ArticleId IdType="pubmed">29473513</ArticleId></ArticleIdList></Reference><Reference><Citation>Vizziello M., Borellini L., Franco G., Ardolino G. Disruption of Mitochondrial Homeostasis: The Role of PINK1 in Parkinson&#x2019;s Disease. Cells. 2021;10:3022. doi: 10.3390/cells10113022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10113022</ArticleId><ArticleId IdType="pmc">PMC8616241</ArticleId><ArticleId IdType="pubmed">34831247</ArticleId></ArticleIdList></Reference><Reference><Citation>Crichton R.R., Dexter D.T., Ward R.J. Brain iron metabolism and its perturbation in neurological diseases. In: Linert W., Kozlowski H., editors. Metal Ions in Neurological Systems. Springer Vienna; Vienna, Austria: 2012. pp. 1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-7091-1001-0_1</ArticleId><ArticleId IdType="pubmed">20809066</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra G., Shenoi R., Anand R., Rajamma U., Mohanakumar K. Reinforcing mitochondrial functions in aging brain: An insight into Parkinson&#x2019;s disease therapeutics. J. Chem. Neuroanat. 2019;95:29&#x2013;42. doi: 10.1016/j.jchemneu.2017.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2017.12.004</ArticleId><ArticleId IdType="pubmed">29269015</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgna-Pignatti C., Rugolotto S., De Stefano P., Zhao H., Cappellini M.D., Del Vecchio G.C., Romeo M.A., Forni G.L., Gamberini M.R., Ghilardi R., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187&#x2013;1193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477202</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddaert N., Sang K.H.L.Q., R&#xf6;tig A., Leroy-Willig A., Gallet S., Brunelle F., Sidi D., Thalabard J.-C., Munnich A., Cabantchik Z.I. Selective iron chelation in Friedreich ataxia: Biologic and clinical implications. Blood. 2007;110:401&#x2013;408. doi: 10.1182/blood-2006-12-065433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-12-065433</ArticleId><ArticleId IdType="pubmed">17379741</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos D., Moreau C., Devedjian J.C., Kluza J., Petrault M., Laloux C., Jonneaux A., Ryckewaert G., Gar&#xe7;on G., Rouaix N., et al. Targeting Chelatable Iron as a Therapeutic Modality in Parkinson&#x2019;s Disease. Antioxid. Redox Signal. 2014;21:195&#x2013;210. doi: 10.1089/ars.2013.5593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2013.5593</ArticleId><ArticleId IdType="pmc">PMC4060813</ArticleId><ArticleId IdType="pubmed">24251381</ArticleId></ArticleIdList></Reference><Reference><Citation>McColgan P., Tabrizi S.J. Huntington&#x2019;s disease: A clinical review. Eur. J. Neurol. 2017;25:24&#x2013;34. doi: 10.1111/ene.13413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13413</ArticleId><ArticleId IdType="pubmed">28817209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wexler A., Wild E., Tabrizi S.J. George Huntington: A legacy of inquiry, empathy and hope. Brain. 2016;139:2326&#x2013;2333. doi: 10.1093/brain/aww165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww165</ArticleId><ArticleId IdType="pmc">PMC4958906</ArticleId><ArticleId IdType="pubmed">27421790</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates G.P., Dorsey R., Gusella J.F., Hayden M.R., Kay C., Leavitt B.R., Nance M., Ross C.A., Scahill R.I., Wetzel R., et al. Huntington Disease. Nat. Rev. Dis. Prim. 2015;1:15005. doi: 10.1038/nrdp.2015.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.5</ArticleId><ArticleId IdType="pubmed">27188817</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald M.E., Ambrose C.M., Duyao M.P., Myers R.H., Lin C., Srinidhi L., Barnes G., Taylor S.A., James M., Groot N., et al. The Huntington&#x2019;s Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington&#x2019;s disease chromosomes. Cell. 1993;72:971&#x2013;983. doi: 10.1016/0092-8674(93)90585-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90585-E</ArticleId><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Squitieri F., Andrew S., Goldberg Y., Kremer B., Spence N., Zelsler J., Nichol K., Theilmann J., Greenberg J., Goto J., et al. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum. Mol. Genet. 1994;3:2103&#x2013;2114. doi: 10.1093/hmg/3.12.2103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/3.12.2103</ArticleId><ArticleId IdType="pubmed">7881406</ArticleId></ArticleIdList></Reference><Reference><Citation>Persichetti F., Srinidhi J., Kanaley L., Ge P., Myers R.H., D&#x2019;Arrigo K., Barnes G.T., MacDonald M.E., Vonsattel J.-P., Gusella J.F., et al. Huntington&#x2019;s disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains. Neurobiol. Dis. 1994;1:159&#x2013;166. doi: 10.1006/nbdi.1994.0019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.1994.0019</ArticleId><ArticleId IdType="pubmed">9173995</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusella J.F., MacDonald M.E., Lee J.-M. Genetic modifiers of Huntington&#x2019;s disease. Mov. Disord. 2014;29:1359&#x2013;1365. doi: 10.1002/mds.26001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26001</ArticleId><ArticleId IdType="pubmed">25154728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.-M., Gillis T., Mysore J.S., Ramos E.M., Myers R.H., Hayden M.R., Morrison P.J., Nance M., Ross C.A., Margolis R.L., et al. Common SNP-Based Haplotype Analysis of the 4p16.3 Huntington Disease Gene Region. Am. J. Hum. Genet. 2012;90:434&#x2013;444. doi: 10.1016/j.ajhg.2012.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.01.005</ArticleId><ArticleId IdType="pmc">PMC3309179</ArticleId><ArticleId IdType="pubmed">22387017</ArticleId></ArticleIdList></Reference><Reference><Citation>Landles C., Sathasivam K., Weiss A., Woodman B., Moffitt H., Finkbeiner S., Sun B., Gafni J., Ellerby L.M., Trottier Y., et al. Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease. J. Biol. Chem. 2010;285:8808&#x2013;8823. doi: 10.1074/jbc.M109.075028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.075028</ArticleId><ArticleId IdType="pmc">PMC2838303</ArticleId><ArticleId IdType="pubmed">20086007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha A.D., Fung V.S. Huntington&#x2019;s disease. Curr. Opin. Neurol. 2012;25:491&#x2013;498. doi: 10.1097/WCO.0b013e3283550c97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e3283550c97</ArticleId><ArticleId IdType="pubmed">22772878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross C.A., Tabrizi S.J. Huntington&#x2019;s disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83&#x2013;98. doi: 10.1016/S1474-4422(10)70245-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70245-3</ArticleId><ArticleId IdType="pubmed">21163446</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel J.P.G., DiFiglia M. Huntington Disease. J. Neuropathol. Exp. Neurol. 1998;57:369&#x2013;384. doi: 10.1097/00005072-199805000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199805000-00001</ArticleId><ArticleId IdType="pubmed">9596408</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss D.J.H., Pardi&#xf1;as A.F., Langbehn D., Lo K., Leavitt B.R., Roos R., Durr A., Mead S., Holmans P., Jones L., et al. Identification of genetic variants associated with Huntington&#x2019;s disease progression: A genome-wide association study. Lancet Neurol. 2017;16:701&#x2013;711. doi: 10.1016/S1474-4422(17)30161-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30161-8</ArticleId><ArticleId IdType="pubmed">28642124</ArticleId></ArticleIdList></Reference><Reference><Citation>Travessa A.M., Rodrigues F.B., Mestre T.A., Ferreira J.J. Fifteen Years of Clinical Trials in Huntington&#x2019;s Disease: A Very Low Clinical Drug Development Success Rate. J. Huntingtons Dis. 2017;6:157&#x2013;163. doi: 10.3233/JHD-170245.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-170245</ArticleId><ArticleId IdType="pubmed">28671135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordasiewicz H.B., Stanek L.M., Wancewicz E.V., Mazur C., McAlonis M.M., Pytel K.A., Artates J.W., Weiss A., Cheng S.H., Shihabuddin L.S., et al. Sustained Therapeutic Reversal of Huntington&#x2019;s Disease by Transient Repression of Huntingtin Synthesis. Neuron. 2012;74:1031&#x2013;1044. doi: 10.1016/j.neuron.2012.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.05.009</ArticleId><ArticleId IdType="pmc">PMC3383626</ArticleId><ArticleId IdType="pubmed">22726834</ArticleId></ArticleIdList></Reference><Reference><Citation>Agust&#xed;n-Pav&#xf3;n C., Mielcarek M., Garriga-Canut M., Isalan M. Deimmunization for gene therapy: Host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol. Neurodegener. 2016;11:64. doi: 10.1186/s13024-016-0128-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0128-x</ArticleId><ArticleId IdType="pmc">PMC5013590</ArticleId><ArticleId IdType="pubmed">27600816</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Calingasan N.Y., Wille E.J., Cormier K., Smith K., Ferrante R.J., Beal M.F. Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson&#x2019;s and Huntington&#x2019;s Diseases. J. Neurochem. 2009;109:1427&#x2013;1439. doi: 10.1111/j.1471-4159.2009.06074.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06074.x</ArticleId><ArticleId IdType="pmc">PMC2866530</ArticleId><ArticleId IdType="pubmed">19476553</ArticleId></ArticleIdList></Reference><Reference><Citation>McGarry A., Auinger P., Kieburtz K.D., Bredlau A.-L., Hersch S.M., Rosas H.D. Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease. Neurol. Clin. Pract. 2022;12:131&#x2013;138. doi: 10.1212/CPJ.0000000000001161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000001161</ArticleId><ArticleId IdType="pmc">PMC9208406</ArticleId><ArticleId IdType="pubmed">35747889</ArticleId></ArticleIdList></Reference><Reference><Citation>Basavarajappa B.S., Subbanna S. Histone Methylation Regulation in Neurodegenerative Disorders. Int. J. Mol. Sci. 2021;22:4654. doi: 10.3390/ijms22094654.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094654</ArticleId><ArticleId IdType="pmc">PMC8125694</ArticleId><ArticleId IdType="pubmed">33925016</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Simon-Sa&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott I.O.C., Mead S. The C9ORF72 expansion mutation: Gene structure, phenotypic and diagnostic issues. Acta Neuropathol. 2014;127:319&#x2013;332. doi: 10.1007/s00401-014-1253-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1253-7</ArticleId><ArticleId IdType="pubmed">24515836</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R., Isaacs A.M. C9orf72-mediated ALS and FTD: Multiple pathways to disease. Nat. Rev. Neurol. 2018;14:544&#x2013;558. doi: 10.1038/s41582-018-0047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdewyn S., Zhao H., Moisse M., Race V., Matthijs G., Reumers J., Kusters B., Schelhaas H.J., Berg L.H.v.D., Goris A., et al. Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012;21:2412&#x2013;2419. doi: 10.1093/hmg/dds055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds055</ArticleId><ArticleId IdType="pmc">PMC3349421</ArticleId><ArticleId IdType="pubmed">22343411</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E., Renton A.E., Mok K., Dopper E.G., Waite A., Rollinson S., Chi&#xf2; A., Restagno G., Nicolaou N., Simon-Sanchez J., et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330. doi: 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z., Zinman L., Grinberg Y., Moreno D., Sato C., Bilbao J.M., Ghani M., Hern&#xe1;ndez I., Ruiz A., Boada M., et al. Investigation of C9orf72 in 4 Neurodegenerative Disorders. Arch. Neurol. 2012;69:1583&#x2013;1590. doi: 10.1001/archneurol.2012.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.2016</ArticleId><ArticleId IdType="pmc">PMC4005900</ArticleId><ArticleId IdType="pubmed">22964832</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x10c;esnik A.B., Darovic S., Mihevc S.P., &#x160;talekar M., Malnar M., Motaln H., Lee Y.-B., Mazej J., Pohleven J., Grosch M., et al. Nuclear RNA foci from C9ORF72 expansion mutation form paraspeckle-like bodies. J. Cell Sci. 2019;132:jcs.224303. doi: 10.1242/jcs.224303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.224303</ArticleId><ArticleId IdType="pubmed">30745340</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon R.A., Bunton-Stasyshyn R.K.A., Fisher E.M., Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain. 2013;136:2342&#x2013;2358. doi: 10.1093/brain/awt097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt097</ArticleId><ArticleId IdType="pmc">PMC3722346</ArticleId><ArticleId IdType="pubmed">23687121</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco D.A., Morfini G., Karabacak N.M., Song Y., Gros-Louis F., Pasinelli P., Goolsby H., Fontaine B.A., Lemay N., McKenna-Yasek D., et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 2010;13:1396&#x2013;1403. doi: 10.1038/nn.2660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2660</ArticleId><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1. Science. 1998;281:1851&#x2013;1854. doi: 10.1126/science.281.5384.1851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.281.5384.1851</ArticleId><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed M., Yang Y., Deng H.-X., Hung W.-Y., Siddique N., Dellefave L., Gellera C., Andersen P.M., Siddique T. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology. 2009;72:1634&#x2013;1639. doi: 10.1212/01.wnl.0000343509.76828.2a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000343509.76828.2a</ArticleId><ArticleId IdType="pmc">PMC2683645</ArticleId><ArticleId IdType="pubmed">19176896</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K., Mhatre M., Mou S., Pye Q.N., Stewart C., West M., Williamson K.S. On the Relation of Oxidative Stress to Neuroinflammation: Lessons Learned from the G93A-SOD1 Mouse Model of Amyotrophic Lateral Sclerosis. Antioxid. Redox Signal. 2006;8:2075&#x2013;2087. doi: 10.1089/ars.2006.8.2075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2006.8.2075</ArticleId><ArticleId IdType="pubmed">17034351</ArticleId></ArticleIdList></Reference><Reference><Citation>Curti D., Rognoni F., Alimonti D., Malaspina A., Feletti F., Tessera S., Finotti N., Rehak L., Mazzini L., Zerbi F., et al. SOD1 activity and protective factors in familial ALS patients with L84F SOD1 mutation. Lateral Scler. Other Motor Neuron Disord. 2002;3:115&#x2013;122. doi: 10.1080/146608202760834111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608202760834111</ArticleId><ArticleId IdType="pubmed">12495572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceroni M., Malaspina A., Poloni T.E., Alimonti D., Rognoni F., Habgood J., Imbesi F., Antonelli P., Alfonsi E., Curti D., et al. Clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation. Neurology. 1999;53:1064. doi: 10.1212/WNL.53.5.1064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.5.1064</ArticleId><ArticleId IdType="pubmed">10496267</ArticleId></ArticleIdList></Reference><Reference><Citation>Juneja T., Pericak-Vance M.A., Laing N.G., Dave S., Siddique T. Prognosis in Familial Amyotrophic Lateral Sclerosis: Progression and Survival in Patients with Glu100gly and Ala4val Mutations in Cu,Zn Superoxide Dismutase. Neurology. 1997;48:55&#x2013;57. doi: 10.1212/WNL.48.1.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.48.1.55</ArticleId><ArticleId IdType="pubmed">9008494</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Tang J., Lan J., Zhang Y., Wang H., Chen Q., Kang Y., Sun Y., Feng X., Wu L., et al. Honokiol alleviated neurodegeneration by reducing oxidative stress and improving mitochondrial function in mutant SOD1 cellular and mouse models of amyotrophic lateral sclerosis. Acta Pharm. Sin. B. 2023;13:577&#x2013;597. doi: 10.1016/j.apsb.2022.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2022.07.019</ArticleId><ArticleId IdType="pmc">PMC9979194</ArticleId><ArticleId IdType="pubmed">36873166</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassina P., Cassina A., Pehar M., Castellanos R., Gandelman M., de Le&#xf3;n A., Robinson K.M., Mason R.P., Beckman J.S., Barbeito L., et al. Mitochondrial Dysfunction in SOD1G93A-Bearing Astrocytes Promotes Motor Neuron Degeneration: Prevention by Mitochondrial-Targeted Antioxidants. J. Neurosci. 2008;28:4115&#x2013;4122. doi: 10.1523/JNEUROSCI.5308-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5308-07.2008</ArticleId><ArticleId IdType="pmc">PMC3844766</ArticleId><ArticleId IdType="pubmed">18417691</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Li L., Chen S., Yang D., Wang Y., Zhang X., Wang Z., Le W. Rapamycin treatment augments motor neuron degeneration in SOD1G93Amouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7:412&#x2013;425. doi: 10.4161/auto.7.4.14541.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.7.4.14541</ArticleId><ArticleId IdType="pubmed">21193837</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud H., Valdmanis P.N., Kabashi E., Dion P., Dupre N., Camu W., Meininger V., Rouleau G.A. Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J. Med. Genet. 2008;46:112&#x2013;114. doi: 10.1136/jmg.2008.062463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2008.062463</ArticleId><ArticleId IdType="pubmed">18931000</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Rouleau G.A., Kabashi E. TARDBP and FUS Mutations Associated with Amyotrophic Lateral Sclerosis: Summary and Update. Hum. Mutat. 2013;34:812&#x2013;826. doi: 10.1002/humu.22319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22319</ArticleId><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Valdmanis P., Dion P., Spiegelman D., McConkey B.J., Velde C.V., Bouchard J.-P., Lacomblez L., Pochigaeva K., Salachas F., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Valdmanis P., Millecamps S., Lionnet C., Blasco H., Mouzat K., Daoud H., Belzil V., Morales R., Pageot N., et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology. 2012;78:1519&#x2013;1526. doi: 10.1212/WNL.0b013e3182553c88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182553c88</ArticleId><ArticleId IdType="pubmed">22539580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaoka A., Arai M., Itokawa M., Arai T., Hasegawa M., Tsuchiya K., Takuma H., Tsuji H., Ishii A., Watanabe M., et al. TDP-43 M337V Mutation in Familial Amyotrophic Lateral Sclerosis in Japan. Intern. Med. 2010;49:331&#x2013;334. doi: 10.2169/internalmedicine.49.2915.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.49.2915</ArticleId><ArticleId IdType="pubmed">20154440</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Oiwa K., Murata Y., Komine O., Sobue A., Endo F., Takahashi E., Yamanaka K. ALS-linked TDP-43M337V knock-in mice exhibit splicing deregulation without neurodegeneration. Mol. Brain. 2020;13:8. doi: 10.1186/s13041-020-0550-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-0550-4</ArticleId><ArticleId IdType="pmc">PMC6971932</ArticleId><ArticleId IdType="pubmed">31959210</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili M.A., Panahi M., Yadav S., Hennings L., Kiaei M. Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int. J. Exp. Pathol. 2013;94:56&#x2013;64. doi: 10.1111/iep.12006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iep.12006</ArticleId><ArticleId IdType="pmc">PMC3575874</ArticleId><ArticleId IdType="pubmed">23317354</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr&#xf9; S., Coni P., Floris A., Littera R., Carcassi C., Sogos V., Brancia C. Reduced stress granule formation and cell death in fibroblasts with the A382T mutation of TARDBP gene: Evidence for loss of TDP-43 nuclear function. Hum. Mol. Genet. 2016;25:4473&#x2013;4483. doi: 10.1093/hmg/ddw276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw276</ArticleId><ArticleId IdType="pubmed">28172957</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanini G., Selleri V., Nasi M., De Gaetano A., Martinelli I., Gianferrari G., Lofaro F.D., Boraldi F., Mandrioli J., Pinti M. Mitochondrial and Endoplasmic Reticulum Alterations in a Case of Amyotrophic Lateral Sclerosis Caused by TDP-43 A382T Mutation. Int. J. Mol. Sci. 2022;23:11881. doi: 10.3390/ijms231911881.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911881</ArticleId><ArticleId IdType="pmc">PMC9570187</ArticleId><ArticleId IdType="pubmed">36233180</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H., Gao K., Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 2014;10:337&#x2013;348. doi: 10.1038/nrneurol.2014.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.78</ArticleId><ArticleId IdType="pubmed">24840975</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado L., Del Bo R., Castellotti B., Ratti A., Cereda C., Penco S., Sorar&#xf9; G., Carlomagno Y., Ghezzi S., Pensato V., et al. Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. J. Med. Genet. 2010;47:190&#x2013;194. doi: 10.1136/jmg.2009.071027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2009.071027</ArticleId><ArticleId IdType="pubmed">19861302</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Stewart H., Dejesus-Hernandez M., Krieger C., Graff-Radford N., Fabros M., Briemberg H., Cashman N., Eisen A., Mackenzie I.R. Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle Nerve. 2010;42:170&#x2013;176. doi: 10.1002/mus.21665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21665</ArticleId><ArticleId IdType="pmc">PMC2969843</ArticleId><ArticleId IdType="pubmed">20544928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticozzi N., Silani V., LeClerc A.L., Keagle P., Gellera C., Ratti A., Taroni F., Kwiatkowski T.J., McKenna-Yasek D.M., Sapp P.C., et al. Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. Neurology. 2009;73:1180&#x2013;1185. doi: 10.1212/WNL.0b013e3181bbff05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bbff05</ArticleId><ArticleId IdType="pmc">PMC2764725</ArticleId><ArticleId IdType="pubmed">19741215</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich M., Shepheard S.R., Verber N., Wyles M., Heath P.R., Highley J.R., Kirby J., Shaw P.J. Neuropathological characterization of a novel TANK binding kinase (TBK1) gene loss of function mutation associated with amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 2019;46:279&#x2013;291. doi: 10.1111/nan.12578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12578</ArticleId><ArticleId IdType="pubmed">31498468</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes J.A., Davies M.C., Collins M.O. TBK1: A new player in ALS linking autophagy and neuroinflammation. Mol. Brain. 2017;10:5. doi: 10.1186/s13041-017-0287-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0287-x</ArticleId><ArticleId IdType="pmc">PMC5288885</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurfinkel Y., Polain N., Sonar K., Nice P., Mancera R.L., Rea S.L. Functional and structural consequences of TBK1 missense variants in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurobiol. Dis. 2022;174:105859. doi: 10.1016/j.nbd.2022.105859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105859</ArticleId><ArticleId IdType="pubmed">36113750</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S., Carr K., Reiley L., Diaz K., Guerra O., Altamirano P., Pagani W., Lodin D., Orozco G., Chinea A. A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int. 2015;6:171. doi: 10.4103/2152-7806.169561.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Deans C., Maggert K.A. What Do You Mean, &#x201c;Epigenetic&#x201d;? Genetics. 2015;199:887&#x2013;896. doi: 10.1534/genetics.114.173492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.114.173492</ArticleId><ArticleId IdType="pmc">PMC4391566</ArticleId><ArticleId IdType="pubmed">25855649</ArticleId></ArticleIdList></Reference><Reference><Citation>Burggren W. Epigenetic Inheritance and Its Role in Evolutionary Biology: Re-Evaluation and New Perspectives. Biology. 2016;5:24. doi: 10.3390/biology5020024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology5020024</ArticleId><ArticleId IdType="pmc">PMC4929538</ArticleId><ArticleId IdType="pubmed">27231949</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F., Yan J., Vemula S.P., Liu E., Yang Y., Chen W., Zheng J.G., Shi Y., Siddique N., Arrat H., et al. SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. Arch. Neurol. 2011;68:1440&#x2013;1446. doi: 10.1001/archneurol.2011.250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.250</ArticleId><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.O., Mandrioli J., Benatar M., Abramzon Y., Van Deerlin V.M., Trojanowski J.Q., Gibbs J.R., Brunetti M., Gronka S., Wuu J., et al. Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron. 2010;68:857&#x2013;864. doi: 10.1016/j.neuron.2010.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.036</ArticleId><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., Bogaert E., Van Damme P., Bosch L.V.D. Inside out: The role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathol. 2016;132:159&#x2013;173. doi: 10.1007/s00401-016-1586-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1586-5</ArticleId><ArticleId IdType="pmc">PMC4947127</ArticleId><ArticleId IdType="pubmed">27271576</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilarino-Guell C., Wider C., Soto-Ortolaza A.I., Cobb S.A., Kachergus J.M., Keeling B.H., Dachsel J.C., Hulihan M.M., Dickson D.W., Wszolek Z.K., et al. Characterization of DCTN1 genetic variability in neurodegeneration. Neurology. 2009;72:2024&#x2013;2028. doi: 10.1212/WNL.0b013e3181a92c4c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a92c4c</ArticleId><ArticleId IdType="pmc">PMC2692178</ArticleId><ArticleId IdType="pubmed">19506225</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki E., Tsuboi Y., Daechsel J., Milnerwood A., Vilarino-Guell C., Fujii N., Mishima T., Oka T., Hara H., Fukae J., et al. A Novel DCTN1 mutation with late-onset parkinsonism and frontotemporal atrophy. Mov. Disord. 2014;29:1201&#x2013;1204. doi: 10.1002/mds.25833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25833</ArticleId><ArticleId IdType="pubmed">24676999</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O., Kiernan M.C., Chi&#xf2; A., Rix-Brooks B., van den Berg L.H. Amyotrophic lateral sclerosis: Moving towards a new classification system. Lancet Neurol. 2016;15:1182&#x2013;1194. doi: 10.1016/S1474-4422(16)30199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Calvo A., Moglia C., Mazzini L., Mora G., PARALS Study Group Phenotypic heterogeneity of amyotrophic lateral sclerosis: A population based study. J. Neurol. Neurosurg. Psychiatry. 2011;82:740&#x2013;746. doi: 10.1136/jnnp.2010.235952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Finegan E., Chipika R.H., Shing S.L.H., Hardiman O., Bede P. Pathological Crying and Laughing in Motor Neuron Disease: Pathobiology, Screening, Intervention. Front. Neurol. 2019;10:260. doi: 10.3389/fneur.2019.00260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00260</ArticleId><ArticleId IdType="pmc">PMC6438102</ArticleId><ArticleId IdType="pubmed">30949121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera L.C., Mathers S., Talman P., Galtrey C., Parkinson M.H., Ganesalingam J., Willey E., Ampong M.A., Ellis C.M., Shaw C.E., et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology. 2009;72:1087&#x2013;1094. doi: 10.1212/01.wnl.0000345041.83406.a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000345041.83406.a2</ArticleId><ArticleId IdType="pmc">PMC2821838</ArticleId><ArticleId IdType="pubmed">19307543</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47((Suppl. S4)):233S&#x2013;241S. doi: 10.1212/WNL.47.6_Suppl_4.233S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.6_Suppl_4.233S</ArticleId><ArticleId IdType="pubmed">8959995</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L., Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Bensimon G., Meininger V., Leigh P., Guillet P. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425&#x2013;1431. doi: 10.1016/S0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinchcliffe M., Smith A. Riluzole: Real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener. Neurol. Neuromuscul. Dis. 2017;7:61&#x2013;70. doi: 10.2147/DNND.S135748.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S135748</ArticleId><ArticleId IdType="pmc">PMC6053101</ArticleId><ArticleId IdType="pubmed">30050378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora J.S., Genge A., Chio A., Estol C.J., Chaverri D., Hern&#xe1;ndez M., Mar&#xed;n S., Mascias J., Rodriguez G.E., Povedano M., et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial. Amyotroph. Lateral Scler. Front. Degener. 2019;21:5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P., De Strooper B., Kivipelto M., Holstege H., Ch&#xe9;telat G., Teunissen C.E., Cummings J., van der Flier W.M. Alzheimer&#x2019;s disease. Lancet. 2021;397:1577&#x2013;1590. doi: 10.1016/S0140-6736(20)32205-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32205-4</ArticleId><ArticleId IdType="pmc">PMC8354300</ArticleId><ArticleId IdType="pubmed">33667416</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloem B.R., Henderson E.J., Dorsey E.R., Okun M.S., Okubadejo N., Chan P., Andrejack J., Darweesh S.K.L., Munneke M. Integrated and patient-centred management of Parkinson&#x2019;s disease: A network model for reshaping chronic neurological care. Lancet Neurol. 2020;19:623&#x2013;634. doi: 10.1016/S1474-4422(20)30064-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30064-8</ArticleId><ArticleId IdType="pmc">PMC9671491</ArticleId><ArticleId IdType="pubmed">32464101</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi S.J., Flower M., Ross C.A., Wild E.J. Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities. Nat. Rev. Neurol. 2020;16:529&#x2013;546. doi: 10.1038/s41582-020-0389-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0389-4</ArticleId><ArticleId IdType="pubmed">32796930</ArticleId></ArticleIdList></Reference><Reference><Citation>Deda H., Inci M., K&#xfc;rek&#xe7;i A., Sav A., Kay&#x131;han K., &#xd6;zg&#xfc;n E., &#xdc;st&#xfc;nsoy G., Kocabay S. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: A 1-year follow-up. Cytotherapy. 2009;11:18&#x2013;25. doi: 10.1080/14653240802549470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14653240802549470</ArticleId><ArticleId IdType="pubmed">19012065</ArticleId></ArticleIdList></Reference><Reference><Citation>Moviglia G.A., Moviglia-Brandolino M.T., Varela G.S., Albanese G., Piccone S., Echegaray G., Martinez G., Blasseti N., Farias J., Farina P., et al. Feasibility, Safety, and Preliminary Proof of Principles of Autologous Neural Stem Cell Treatment Combined with T-Cell Vaccination for ALS Patients. Cell Transplant. 2012;21:57&#x2013;63. doi: 10.3727/096368912X633770.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368912X633770</ArticleId><ArticleId IdType="pubmed">22507681</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>